Here we correlated the simultaneous expression of CD133 and EpCAM with malignancy of breast tumor cells revealing the unprecedented evidence that a CD133+/EpCAM+ sub-population with more aggressive potential is present in the MDA-MB-231 cell line, showing a basal-B TNBC phenotype [25]. This evidence concerns the gene EPCAM and breast neoplasm.